| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5744475 | TAIHO ONCOLOGY | Uracil derivatives, and antitumor effect potentiator and antitumor agent containing the same |
Mar, 2016
(8 years ago) | |
| US9527833 | TAIHO ONCOLOGY | Stable crystal form of tipiracil hydrochloride and crystallization method for the same |
Jun, 2034
(10 years from now) | |
| US10457666 | TAIHO ONCOLOGY | Stable crystal form of tipiracil hydrochloride and crystallization method for the same |
Jun, 2034
(10 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6479500 | TAIHO ONCOLOGY | Agents for alleviating side effects |
Mar, 2020
(4 years ago) | |
| US7799783 | TAIHO ONCOLOGY | Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor |
Dec, 2026
(2 years from now) | |
| USRE46284 | TAIHO ONCOLOGY | Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor |
Sep, 2029
(5 years from now) | |
| US9943537 | TAIHO ONCOLOGY | Antitumor agent and antitumor effect enhancer |
Sep, 2034
(10 years from now) | |
| US10456399 | TAIHO ONCOLOGY | Method for treating cancer patients with severe renal impairment |
Feb, 2037
(12 years from now) | |
| US10960004 | TAIHO ONCOLOGY | Method for treating cancer patients with severe renal impairment |
Feb, 2037
(12 years from now) | |
Lonsurf is owned by Taiho Oncology.
Lonsurf contains Tipiracil Hydrochloride; Trifluridine.
Lonsurf has a total of 9 drug patents out of which 2 drug patents have expired.
Expired drug patents of Lonsurf are:
- US6479500
- US5744475
Lonsurf was authorised for market use on 22 September, 2015.
Lonsurf is available in tablet;oral dosage forms.
Lonsurf can be used as treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-vegf biological therapy, and if ras wild-type, an anti-egfr therapy, treatment of metastatic colorectal cancer alone or with bevacizumab in patients previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-vegf biological therapy, and if ras wild-type, an anti-egfr therapy, treatment of metastatic gastric or gja in severely renally impaired patients treated with at least two lines of chemotherapy that included a fluoropyrimidine, a platinum, a taxane or irinotecan, and if appropriate, her2/neu-targeted therapy, treatment of metastatic colorectal cancer with bevacizumab in patients previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-vegf biological therapy, and if ras wild-type, an anti-egfr therapy.
Drug patent challenges can be filed against Lonsurf from 23 September, 2019.
The generics of Lonsurf are possible to be released after 03 February, 2037.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-229) | Feb 22, 2026 |
| New Indication(I-794) | Feb 22, 2022 |
| New Chemical Entity Exclusivity(NCE) | Sep 22, 2020 |
Drugs and Companies using TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE ingredient
NCE-1 date: 23 September, 2019
Market Authorisation Date: 22 September, 2015
Treatment: Treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-vegf biological therapy, and if...
Dosage: TABLET;ORAL
LONSURF family patents
